World Antimicrobial Resistance Awareness Week 2026
Today marks the start of World AMR Awareness Week 2026, highlighting the urgent need for action against antimicrobial resistance (AMR). The theme for this year, “One Health, One Action: Prevent AMR Now”, emphasises that human, animal, plant and environmental health are closely connected, and that addressing AMR requires coordinated action between different sectors.

Here at ID-CARE we are involved in multiple projects focussed on AMR, in particular the projects REVERSE, SAVE, EPI-Net and PRIMAVERA.
REVERSE is a Horizon 2020 EU-Funded project for which the University of Verona is a partner and Work Package lead. The project develops and implements cost-effective strategies and tools for the prevention and clinical management of healthcare-associated infections due to multidrug-resistant organisms, aiming to reduce the burden of antimicrobial resistance in high-prevalence healthcare settings. Work Package 4, which the ID-CARE team leads, focusses on the development and organisation of the Antibiotic Stewardship Programme.
SAVE, a project run by the University Hospital of Verona, aims to promote awareness and training of healthcare personnel regarding antibiotic prescriptions. In February 2023, the Firstline mobile App, developed through this project, was launched and made accessible to all the healthcare professional at the University Hospitals of Verona, following its two years of development, and successful pilot phase. The app, through guidance of appropriateness of various treatments, aims to reduce the use of antibiotics. During the pilot phase, the app was adopted within the COVID wards, the Paediatric area and in the two Emergency Departments of the hospitals.
EPI-Net is a network of epidemiological surveillance experts and stakeholders in Europe, mapping current systems; to define methodological challenges, and develop research strategy for epidemiological studies; to pursue consensus for best-practices; and support research and development for new, effective antibiotics.
PrIMAVeRa aims to develop comprehensive mathematical models to predict the impact of vaccines and monoclonal antibodies (mAbs) on the reduction of antimicrobial resistance (AMR), thereby enabling decision-makers to prioritise the most promising new vaccines and mAbs.



Comments